Adagene Inc.

Merck Sharp + Dohme Corp.

Sbi Incubation Co., Ltd.

Y's Therapeutics Co., Ltd.

Peter Peizhi Luo

Yan Li

Fangyong Du

Pingyu Zhong

Kevin Caili Wang

Feng Dong

Rose M Cubbon

Laurence B Peterson

Guizhong Liu

Mark Hsieh

Jon H Condra

Andrei Alexandrovich Golosov

Jun Chen

Holly A Hammond

Ayesha Sitlani

Jeffrey T Blue

Weirong Wang

Shilpa Pandit

Xinwei Wang

Joseph C Santoro

Denise K Nawrocki

Dana D Wood

Henryk Mach

Sonia M Gregory

Chikao Morimoto

Yan Ni

Xiaohong She

Peter Cheung

Teikichi Aoyagi

Heidi Yoder

Zhongzong Pan

Timothy McCabe

Jian Wang

Laura Orsatti

Noel Byrne

Stephen Soisson

Gopalakrishnan Parthasarathy

Jun Lu

Sujata Sharma

Kevin Caili Wangr

Timothy Mccabe

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

Dynamic human heavy chain antibody libraries

Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.

Masked activatable CD137 antibodies

Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

Method for treating cancer using anti-CD137 antibody

Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).

Anti-CTLA4 antibodies and methods of making and using the same

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

Dynamic human antibody light chain libraries

Methods and systems for autoinduction of gene expression, without the need to add exogenous inducers. A dual genetic element system, which includes a first, high copy number genetic element comprising a first gene of interest that is under the control of an inducible promoter, and a second, low copy number genetic element comprising a gene encoding a transcriptional factor which, upon expression, regulates transcription from the inducible promoter, wherein activation of transcription from the inducible promoter does not require addition of an exogenous inducer.

Methods and systems for autoinduction of protein expression

The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

Anti-CD137 molecules and use thereof

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

AX132 PCSK9 antagonists

AX1 PCSK9 antagonists

The present invention provides expression vectors and helper display vectors which can be used in various combinations as vector sets for display of polypeptides on the outer surface of eukaryotic host cells. The expression vector of the invention can be used alone for soluble expression without having to change or reengineer the display vectors. The display systems of the invention are particularly useful for displaying a genetically diverse repertoire or library of polypeptides on the surface of yeast cells, and mammalian cells.

Eukaryotic cell display systems

1B20 PCSK9 antagonists

1D05 PCSK9 antagonists

The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.

Anti-CD26 antibodies and methods of use thereof

Growing community of inventors

Lansdale, PA, United States of America

Peter Peizhi Luo